Minerva Neurosciences, Inc.
1 day chart
Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.
Sign up and fund a new Wall St account and get a full U.S. share.
T&Cs applyAbout NERV
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Find out what a historical investment in Minerva Neurosciences, Inc. would be worth today using our NERV stock calculator.
$11.19M
-
0.00%
2.1K
$1.61
$1.57
$1.61
$3.69
$1.15
Ready to start your investing journey with Stake?
Open an accountNERV FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in NERV
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in NERV
on Stake
Buy NERV from US$3 brokerage
Invest in 9,500+ U.S. stocks and ETFs
Own a slice of NERV from only US$10 with fractional shares
